Roivant Sciences (ROIV) Non-Current Deffered Revenue (2022)
Roivant Sciences (ROIV) reported Non-Current Deffered Revenue of $11.9 million for Q3 2022, down 9.47% quarter-over-quarter from $13.1 million in Q2 2022.
Roivant Sciences (ROIV) Non-Current Deffered Revenue (2022) Analysis & Trends
Roivant Sciences has reported Non-Current Deffered Revenue for 1 years, with the latest figure at $11.9 million in Q3 2022.
- For the quarter ending Q3 2022, Non-Current Deffered Revenue changed N/A year-over-year to $11.9 million; the trailing twelve-month figure through Sep 2022 stood at $11.9 million (changed N/A YoY), and the FY2022 full-year result was $13.7 million, changed N/A from the prior year.
- Non-Current Deffered Revenue for Q3 2022 stood at $11.9 million, down from $13.1 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $13.7 million in Q1 2022, with the low at $11.9 million in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Roivant Sciences | 21.82 Bn | 22.59 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 11.90 Mn |
| Jun 30, 2022 | 13.15 Mn |
| Mar 31, 2022 | 13.74 Mn |